TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07207369: A Multicenter, Cohort-design, Double-blind, Randomized, Parallel-group, Controlled Study to Evaluate the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars

Sponsor: AbbVie · Phase: PHASE3 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 395 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$7,400,472

Rescue Site Savings

+$4,872,588

Unlock Full NCT07207369 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07207369 Rescue Dossier →